Leukemia Research
Volume 29, Issue 6 , Pages 609-615 , June 2005

High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience

  • Alexandra Böhm

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    • ,
  • Maria Piribauer

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    • ,
  • Friedrich Wimazal

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    • ,
  • Klaus Geissler

      Affiliations

    • Fifth Medical Department – Oncology, Hospital Lainz, Vienna, Austria
    • ,
  • Heinz Gisslinger

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    • ,
  • Paul Knöbl

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    • ,
  • Ulrich Jäger

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    • ,
  • Christa Fonatsch

      Affiliations

    • Institute of Medical Biology, Vienna, Austria
    • ,
  • Paul A. Kyrle

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    • ,
  • Peter Valent

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    • ,
  • Klaus Lechner

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    • ,
  • Wolfgang R. Sperr

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43 1 40400 6085; fax: +43 1 402 69 30.

Received 14 July 2004 ,Accepted 26 October 2004.

References 

  1. Battista R, Bassan R, D’Emilio A, Dragone P, Viero P, Dini E, et al. Short-term remission induction and consolidation therapy for adult acute myelogenous leukemia. Hematol Oncol. 1991;9:43–52
  2. Harousseau JL, Milpied N, Briere J, Desablens B, Leprise PY, Ifrah N, et al. Double intensive consolidation chemotherapy in adult acute myeloid leukemia. J Clin Oncol. 1991;9:1432–1437
  3. Hiddemann W, Buchner T. Current status and perspectives of therapy for acute myeloid leukemia. Semin Hematol. 2001;38:3–9
  4. Rowe JM, Liesveld JL. Treatment and prognostic factors in acute myeloid leukaemia. Baillieres Clin Haematol. 1996;9:87–105
  5. Cassileth PA, Harrington DP, Hines JD, Oken MM, Mazza JJ, McGlave P, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol. 1988;6:583–587
  6. Bennett JM, Andersen JW, Cassileth PA. Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group (ECOG) experience. Leuk Res. 1991;15:222–223
  7. Bloomfield CD. Postremission therapy in acute myeloid leukemia. J Clin Oncol. 1985;3:1570–1572
  8. Greinix HT, Nachbaur D, Krieger O, Eibl M, Knobl P, Kalhs P, et al. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol. 2002;117:914–923
  9. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukaemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217–223
  10. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood. 1992;79:1924–1930
  11. Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer. 2001;92:1059–1073
  12. Zittoun R, Liso V, Mandelli F, Rotoli B, de Witte T, Gattringer C, et al. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group. Leukemia. 1992;6:76–77
  13. Willemze R, Jager U, Jehn U, Stryckmans P, Bury J, Suciu S, et al. Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study. Eur J Cancer Clin Oncol. 1988;24:1721–1725
  14. Stasi R, Venditti A, Del Poeta G, Aronica G, Abruzzese E, Pisani F, et al. High-dose chemotherapy in adult acute myeloid leukemia: rationale and results. Leuk Res. 1996;20:535–549
  15. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, et al. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood. 1992;80:2977–2982
  16. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukaemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896–903
  17. Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T, et al. The Hellenic Cooperative Group Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer. 2003;97:1721–1731
  18. Palmieri S, Sebastio L, Mele G, Annunziata M, Annunziata S, Copia C, et al. High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21). Leuk Res. 2002;26:539–543
  19. Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999;94:3694–3701
  20. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–458
  21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French–American–British Cooperative Group. Ann Intern Med. 1985;103:620–625
  22. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24:17–31
  23. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075–4083
  24. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173–4179
  25. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, et al. Etoposide in acute nonlymphocytic leukaemia. Australian Leukemia Study Group. Blood. 1990;75:27–32
  26. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, et al. American Society of Clinical Oncology Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;15:1519–1538
  27. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813–819
  28. Byrd JC, Ruppert AS, Mrozek K, Carroll AJ, Edwards CG, Arthur DC, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;15:1087–1094
  29. Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, et al. French Acute Myeloid Leukemia Intergroup; Groupe Ouest-Est des Leucemies Aigues Myeoblastiques; Leucemies Aigues Myeoblastiques de l’Enfant; Acute Leukemia French Association; Bordeaux–Grenoble–Marseille–Toulouse cooperative groups Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003;102:462–469
  30. Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17:3767–3775
  31. Büchner T, Hiddemann W, Berdel W, Wormann B, Schoch C, Loffler H, et al. Acute myeloid leukemia: treatment over 60. Rev Clin Exp Hematol. 2002;6:46–59
  32. Sperr WR, Hauswirth AW, Wimazal F, Knobl P, Geissler K, Valent P. Treatment concepts for elderly patients with acute myeloid leukemia. Wien Klin Wochenschr. 2003;115:505–514
  33. Rombouts WJ, Lowenberg B, van Putten WL, Ploemacher RE. Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene. Leukemia. 2001;15:1046–1053
  34. Moreno I, Martin G, Bolufer P, Barragan E, Rueda E, Roman J, et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica. 2003;88:19–24
  35. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–1759
  36. Kimby E, Nygren P, Glimelius B SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol. 2001;40:231–252
  37. Sperr WR, Piribauer M, Wimazal F, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I, et al. A novel effective and safe consolidation for patients with AML aged over 60: intermediate dose ARA-C (2 × 1g/m2 on days 1, 3 and 5). Clin Cancer Res. 2004;10:3965–3971

PII: S0145-2126(04)00381-9

doi: 10.1016/j.leukres.2004.10.009

Leukemia Research
Volume 29, Issue 6 , Pages 609-615 , June 2005

Article Tools

* Image Usage & Resolution